Company: Axial Biotherapeutics
Job title: CEO
Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund.
Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group.
He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.
Live Q&A 4:10 pm
day: Day Two
Harnessing the Gut-Brain Axis to Develop Therapeutics for Neurodevelopmental Disorders 3:30 pm
Overview of mechanisms of action involved in treating neurological disorders via the gut-brain axis Neurodevelopmental studies, advancing AB-2004 to help a significantly underserved ASD population Examining exploratory endpoints including changes in bacterial metabolite levels, GI function, gut microbiome and behavior Building a unique class of gut-targeted programs for neuropsychiatric and neurodegenerative diseasesRead more
day: Day Two